|
Revenue from operations stood at Rs 2,033.96 crore during the quarter, registering a growth of 27.05% as compared with Rs 1,600.95 crore recorded in the corresponding quarter previous year.
Profit before tax was at Rs 225.36 crore in Q2 FY24, marginally up as compared with Rs 223.82 crore recorded in Q2 FY23.
EBITDA before forex (gain) and loss, other income and unichem acquisition cost stood at Rs 358.77 crore in Q2 FY24, registering a growth of 32% YoY.
The firm reported total formulations of Rs 1,315.73 crore in Q2 FY24, up 12% as compared with Rs 1,170.11 crore posted in Q2 FY23. Domestic formulations jumped 10% to Rs 844.99 crore in Q2 FY24. Under exports, revenue from branded business stood at Rs 145.94 crore (up 15% YoY), institutional business was at Rs 60.59 crore (down 21% YoY), generics business stood at Rs 264.21 crore (up 32% YoY) during the period under review.
The company’s total APIs stood at Rs 334.91 crore during the quarter, up 6% as compared with Rs 316.77 crore posted in the same period a year ago. Revenue from domestic API declined 5% YoY to Rs 84.93 crore while exports jumped 10% to Rs 249.98 crore in Q2 FY24.
Meanwhile, the company’s board has declared an interim dividend of Rs 2 per share for the financial year 2023-24. The record date is fixed as on 22 November 2023. The dividend will be paid to the shareholders on or before 5 December 2023.
Ipca Laboratories is an Indian multinational pharmaceutical company. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally.
The scrip rose 0.69% to Rs 1,054 on the BSE.
|